Use of IMRT to treat prostate cancer, which carries a reimbursement rate approximately 50 percent higher than conformal radiotherapy, skyrocketed from zero in 2000 to 82.1 percent in 2009 among postprostatectomy patients. Despite the swift uptake, IMRT may not provide morbidity benefits among these patients, according to a study published online May 20 in JAMA Internal Medicine.

Indeterminate renal masses detected on CT colonography (CTC) warrant follow-up as they have a one-in-five chance of malignancy, according a review of research of extracolonic findings on CTC published in the June issue of Academic Radiology.